History timeline

2019

• PharmaSynth was awarded with GMP certificate for all of our precursors and reference compounds.

2018

• Audited by customers on our GMP production.

2017

• [¹¹C]UCB-J precursor and reference compound added to the portfolio.

2015 - 2016

• Successfully audited by the State Agency of Medicines for API registration and GMP cetrificate. 
  
• Re-audited by two companies for GMP production.
  

2013 - 2014  

• PharmaSynth has a new image and new website.
  
• Construction of quality control facility starts.
  

2012

• A number of more than 90 molecules in our product portfolio is reached.
  
• Re-audited by two companies for GMP production.
  

2011

• First synthesis of β-FDHT.
  

2010

• PBR28, Tosylethyl-PE2I are produced and distributed by PharmaSynth.
  

2009

• New products added to our portfolio, such as: (+)-DTBZ, MePPEP.
  

2008

• Introduction of PIB.
  
• First audits conducted successfully by two major pharmaceutical companies.
  
• Production facilities expands to two fully equipped laboratories.
  

2007

• Introduction of new products: FLB457, FD2-MeNER, β-CFT.
  
• Partnership with Karolinska Institute, Sweden, for test-labeling services of our precursors.
  

2006

• Collaboration agreement with NARD Institute, Japan, for molecule development and distribution in Asian countries.
  
• Partnership with Tartu University, Estonia, for quality control services.
  
• Synthesis and commercialization of DASB, PK11195, NER, D2-Deprenyl.
  

2005

• The construction of the modern laboratories, that can facilitate GMP production, has started.
  
• Synthesis and commercialization of PE2I, MADAM, TMSX.
  

2004

• PharmaSynth is founded in Estonia, with offices and production facilities in Tartu Science Park, as a response to the growing demand of certified molecules used in PET and SPECT imaging studies.